Coherus Oncology, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Toripalimab at $13.6 million, 95% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
51
|
14
|
12
|
13
|
12
|
10
|
8
|
8
|
6
|
| Toripalimab |
49
+59.6%
share 96.1%
|
14
+36.7%
share 95.1%
|
12
+60.6%
share 95.9%
|
12
+64.3%
share 97.0%
|
11
+91.5%
share 96.5%
|
10
share 97.1%
|
7
share 96.7%
|
8
share 97.3%
|
6
share 96.4%
|
| Product And Service Other |
2
+103.8%
share 3.9%
|
1
+135.3%
share 4.9%
|
1
+102.0%
share 4.1%
|
0
+83.9%
share 3.0%
|
0
+82.7%
share 3.5%
|
0
share 2.9%
|
0
share 3.3%
|
0
share 2.7%
|
0
share 3.6%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CHRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1512762
- Former names
- Coherus BioSciences, Inc. (until May 28, 2025); BioGenerics, Inc. (until Jan 3, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.